However, as we do not yet fully understand the differential dependency of cell lines on CSN5 and how these differences are based on genetic or epigenetic differences, comprehensive studies addressing the effects of CSN5i-3 on oncogenic and tumour suppressive CRLs are critical to facilitate the selection of cancer indications best suited for the treatment with a CSN5 inhibitor. This evidence concerns the gene COPS5 and neoplasm.